About MPD-RC

Welcome

The Myeloproliferative Disorders Research Consortium (MPD-RC) is an international, multi-institutional non profit consortium funded by the National Cancer Institute and set up to coordinate, facilitate, and perform basic and clinical research investigating the genetic and cellular mechanisms of the Philadelphia Chromosome (Ph) negative myeloproliferative neoplasms (MPNs). The ultimate goal is to develop novel therapeutic strategies to improve the management of patients with this type of diseases. More


Info for Patients

Find out more about Myeloproliferative Neoplasms, their symptoms, diagnosis and treatment. More

Find patient support group and share your experience with other patients and their families. More
Patients

New Trial: MPD-109!

News

We are now recruiting subjects for the trial MPD-RC 109: Combination Therapy of Ruxolitinib and Decitabine in patients with Myeloproliferative Neoplasms in Accelerated and Blast Phase Disease.

» 109 Protocol on ClinicalTrials.gov
superadmin on May 05 2014 11:31:46 · Read More · 186 Reads · Print

MPD-114

News

We are now recruiting subjects for the trial MPD-RC 114: Exploring the Potential of Dual Kinase JAK 1/2 Inhibitor Ruxolitinib (INC424) with Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis.

» 114 Protocol on ClinicalTrials.gov
superadmin on November 13 2013 10:00:11 · Read More · 412 Reads · Print

MPD-111

News

We are recruiting patients to the study 111.

»111 Protocol on ClinicalTrials.gov
superadmin on October 27 2011 14:34:41 · Print

MPD-112

News

We are recruiting patients for the clinical trial 112.

»112 Protocol on ClinicalTrials.gov
superadmin on September 24 2011 00:00:00 · Print